Figure 3From: Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study SF-36a domain scores at baseline and at the ends of part 1 and 3 in adults. aData are presented as the mean.Back to article page